TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of asthma ≥ 1 year and diagnosed before 40 years old~* Uncontrolled asthma with double therapy only on high doses of Inhaled CorticoSteroid (ICS) in combination with Long-Acting Beta2 Agonist (LABA) with ACQ-7 (Asthma Control Questionnaire) ≥1.5~* Pre-bronchodilator FEV1 \<80% of the predicted normal value~* Positive reversibility test~* At least 1 documented asthma exacerbation in the previous year~Exclusion Criteria:~* Pregnant or lactating women~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)~* Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks prior screening~* Current smoker or ex-smoker (\>= 10 packs year)~* Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks prior screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CHF 5993 200/6/12.5 µg (Type: EXPERIMENTAL): Treatment A:~CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB
- CHF 1535 200/6 µg (Type: ACTIVE_COMPARATOR): Treatment B:~CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF
- CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg (Type: ACTIVE_COMPARATOR): Treatment C (open-label arm):~CHF 1535 200/6 µg: 2 inhalations bid~+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Taxotere Prostate Cancer New Indication Registration Trial in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven prostate adenocarcinoma~* Androgen independent prostate Cancer S/P orchiectomy and/or LHRH agonist Testosterone \< 50 ng/dl (ie 1.735 nmol/l)~* Documented progressive disease~* Patients should have achieved stable analgesia for 7 days~* Karnofsky Performance Status ≥ 70~* No prior treatment with cytotoxic agent (except estramustine)~* Normal cardiac function must be confirmed by Left ventricular ejection fraction~* Adequate organ function:~  1. Hematology:~     * Neutrophils \> 1.5 x 10\^9/L~    * Hemoglobin \> 10 g/dl. Erythropoietin use is allowed, but red blood cell transfusion to upgrade the hemoglobin level is not allowed~    * Platelets \> 100 x 10\^9/L~ 2. Hepatic function:~     * Total bilirubin \< the upper-normal limit of the institution.~    * Alanine aminotransferase and Aspartate transaminase \< 1.5 times the upper-normal limit of the institution.~ 3. Renal function:~     * Creatinine \< 1.5 times the upper normal limit (ie National Cancer Institution grade \< 1)~* No brain or leptomeningeal metastases~Exclusion Criteria:~* Prior radiotherapy to \>25% of bone marrow (whole pelvic irradiation is not allowed)~* prior cytotoxic chemotherapy, except monotherapy with estramustine~* prior isotope therapy~* history of another cancer within the preceding five year~* symptomatic peripheral neuropathy grade ≥ 2~* other serious illness or medical condition:~  1. Congestive heart failure even if controlled. Previous history of myocardial infarction or angina pectoris within 1 year from study entry, uncontrolled hypertension or uncontrolled arrhythmias.~ 2. Active uncontrolled infection~ 3. Peptic ulcer, unstable diabetes mellitus or other contraindications for the use of corticosteroids.~ 4. Auto-immune disease (lupus, sclerodermia, rheumatoid polyarthritis)~* treatment with any other anti-cancer therapy~* treatment with bisphosphonates~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
- 2 (Type: ACTIVE_COMPARATOR): Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Lifestyle Interventions to Overweight and Obese Patients in Primary Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age 18-40 BMI ≥ 25 kg/m 2 Agreeing to participate in the study Not having a diagnosed chronic disease To be able to ambulate To be cooperative~Exclusion Criteria:~* Receiving medical treatment~* Secondary obesity (hypothyroidism, Cushing\&#39;s disease, etc.)~* Chronic disease (cardiovascular diseases, pulmonary diseases, presence of diabetes mellitus, liver diseases, renal diseases)~* Having hyperlipidaemia under treatment~* Cancer~* Pregnancy or breastfeeding~* Psychiatric disorder~* Orthopaedic or neurological disease that may prevent walking~* Are currently taking weight loss medication or enrolled in another weight loss program~* Having previously undergone obesity surgery or having surgery planned during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: None

Study Arms:
- Intervention group (Type: None): They were given a calorie-restricted diet and exercise plan by a dietician or physiotherapist at their first visit, and were followed up by telephone calls at weeks 2, 4, 6, 8 and 10 over 12 weeks.
- Control-1 group (Type: None): During the initial medical interview, the participants were given a calorie-restricted diet programme by a dietician and an exercise programme by a physiotherapist; they were followed up over 12 weeks with telephone calls at week 4.
- Control-2 group (Type: None): During the initial medical interview, the participants were given a calorie-restricted diet programme by a dietician and an exercise programme by a physiotherapist; they were followed up over 12 weeks with telephone calls at week 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with autosomal dominant polycystic kidney disease (ADPKD) aged 18-55~* estimate glomerular filtration rate (GFR) at or above ≥ 50 ml/min/1.73 m2 by any GFR formula~* Normal liver enzymes (ALT/AST)~* fasting blood glucose between 70 and120~* for female patients, a willingness to use double contraception to avoid pregnancy while in study~* able to give informed consent~* In the opinion of the investigator, high likelihood of progressive kidney disease~Exclusion Criteria:~* diabetes, defined as any of the following: fasting blood sugar \> 130 times two, HgbA1C \> 7, on any blood sugar lowering medication, or past diagnosis of diabetes not occurring during pregnancy~* uncontrolled hypertension as determined by the examining physician~* history of impaired systolic function (ejection fraction \< 50%) by previous echocardiogram or known ischemic cardiovascular disease~* findings suggestive of a kidney disease other than ADPKD~* systemic illness requiring immunosuppressive or anti-inflammatory agents~* congenital absence of a kidney or history of a total nephrectomy~* history of cyst reduction or partial nephrectomy~* history of renal cyst aspiration within the previous year~* History of bladder cancer, or gross hematuria~* inability to undergo MRI due to implantable devices or foreign objects that preclude MRI~* active renal transplant~* allergy or sensitivity to any of the components of the test materials~* institutionalized~* currently pregnant or plans to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Arm (Type: PLACEBO_COMPARATOR): Subject will be on placebo
- Pioglitazone Arm (Type: ACTIVE_COMPARATOR): Subject will be on pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who received study agent at the start of study CNTO1275CRD3001 or CNTO1275CRD3002 and completed the Week 8 visit. Exclusion Criteria:~* Patients who underwent a Crohn's disease-related surgery since the start of induction study CNTO1275CRD3001 or CNTO1275CRD3002~* Patients who started a protocol prohibited medication since the start of studies CNTO1275CRD3001 and CNTO1275CRD3002~* Patients with protocol-specified changes to their concomitant medications due to Crohn's disease (due to lack of efficacy) since the start of studies CNTO1275CRD3001 and CNTO1275CRD3002

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: PLACEBO_COMPARATOR): Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).
- 002 (Type: EXPERIMENTAL): Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).
- 003 (Type: EXPERIMENTAL): Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).
- 004 (Type: EXPERIMENTAL): Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.
- 005 (Type: EXPERIMENTAL): Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.
- 006 (Type: PLACEBO_COMPARATOR): Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Men or women age ≥ 18 years old~* Stable dose combination of metformin and sulfonylurea~* HbA1c ≥7.7% and ≤11.0%~Exclusion Criteria:~* Type 1 diabetes mellitus or diabetes insipidus~* Recent cardiovascular events~* Kidney or urological disorders~* Hepatic disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 10 mg tablet (Type: EXPERIMENTAL): None
- matching placebo tablet (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent;~* Age ≥18 years;~* Histologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as documented via imaging (within 6 weeks of Screening);~* Subject not a candidate for surgery;~* Completion of at least one standard of care IV chemotherapy course for subjects in the dose escalation phase of the study. IV chemotherapy will be initiated prior to first NanoPac injection for subjects in the second and third phases. Hematologic recovery must be confirmed prior to study entry;~* Performance Status (ECOG) 0-1 at study entry;~* Life expectancy of at least 3 months;~* Adequate marrow, liver, and renal function at study entry:~  * ANC ≥ 1.5 x 109/L~ * Hemoglobin ≥ 9.5 grams/dL~ * Platelets ≥ 75 x 109/L~ * Total bilirubin ≤ 1.5x institutional ULN~ * AST/ ALT ≤ 2.5x institutional ULN~ * Creatinine ≤ 1.5x institutional ULN~* Effective contraception if the risk of conception exists.~Exclusion Criteria:~* Thrombotic or embolic events;~* Acute or subacute intestinal occlusion;~* History of inflammatory bowel disease;~* Known hypersensitivity to study drugs;~* Known drug or alcohol abuse;~* Pregnant or breastfeeding women;~* Previous or concurrent history of non-pancreatic malignancy except for non-melanoma skin cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation: NanoPac® 6 mg/mL (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
- Dose Escalation: NanoPac® 10 mg/mL (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
- Dose Escalation: NanoPac® 15 mg/mL (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
- Second Phase: NanoPac® at Best Dose (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
- Third Phase: NanoPac® at Best Dose (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: China ADVATE PTP Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Ethnic Chinese~* is of any age~* has a documented diagnosis of severe or moderately severe hemophilia A (congenital FVIII deficiency: baseline Factor VIII (FVIII) ≤ 2%)~* has documented and verified \>50 exposure days (EDs) to FVIII (recombinant or plasma derived)~* is receiving on-demand treatment with FVIII at the time of enrolment in this study~* has negative history of inhibitor development~* is HIV negative or HIV positive with stable disease and CD4+ count ≥ 200 cells per mm\^3~* is negative for Hepatitis C virus (HCV); Or participant is HCV positive with chronic stable hepatitis as assessed by investigator~Main Exclusion Criteria:~* has prior history of hypersensitivity or anaphylaxis associated with receipt of FVIII~* is diagnosed with other bleeding disorder(s) other than hemophilia A, including but not limited to thrombocytopenia (platelet count \< 100000 /mL)~* has been exposed to an investigational product (IP) within 30 days prior to the screening visit or is scheduled to participate in another clinical study involving an IP or investigational device during participation in the study~* is planned, or likely to have surgery during the study period~* has end-stage renal failure or evidence of a severe or uncontrolled systemic disease as judged by the investigator~* has active hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels \> 5 times the upper limit of normal)~* has clinical or laboratory evidence of severe liver impairment including (but not limited to) a recent \& persistent international normalized ratio (INR) \>1.4, and/or the presence of splenomegaly and/or significant spider angioma on physical exam, and/or a history of esophageal hemorrhage or documented esophageal varices~* is a family member of the investigator or site staff

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Previously Treated Patients (PTPs) (Type: EXPERIMENTAL): PTPs will participate sequentially with:~Part 1: Pharmacokinetic parameters of ADVATE measured in subset of 24 participants, consisting of:~* 12 adults (\>12 years of age)~* 12 children (≤12 years of age)~Part 2: On-demand treatment with ADVATE for 6 months~Part 3: Prophylaxis regimen with ADVATE for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The cirrhotic malnourished patients who were diagnosed as liver cancer preoperatively and underwent hepatectomy were consecutively enrolled.~Exclusion Criteria:~* Contraindication for hepatectomy, including gastrointestinal hemorrhage, severe hemorrhagic disorders, explicit acute nonspecific infectious lesion, overt ascites, Child-Pugh Score C, indocyanine green retention rate at 15min (ICGR15)\>30%(12), serum hepatitis B virus (HBV)-DNA\>126 copies/ml and serum alanine aminotransferase (ALT) \> 2×ULN, serum triglycerides\>2.0 mmol/L, circulatory shock, stroke, acute myocardial infarction, renal failure, coma of unknown cause~* Pregnancy~* Age of\<18y or\>75y~* Performed intraoperative ablation~* Unresectable tumor during operation~* Allergic reactions against fish or egg proteins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: ACTIVE_COMPARATOR): For postoperative parenteral nutrition, only Structolipid applied for 5 consecutive days.
- Trial group (Type: EXPERIMENTAL): For postoperative parenteral nutrition, Omega-3 Fatty Acid-Based Parenteral Nutrition (20% Structolipid and 10% Omegaven) were applied for 5 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized.~* Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1.~* Use of one (1), but no more than two (2) concomitant marketed AEDs at the time of trial entry.~Exclusion Criteria:~* Subjects on felbamate with less than 18 months exposure.~* Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months.~* Presence of known pseudoseizures within the last year.~* Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors.~* Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Viaskin Pertussis Vaccine Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has provided written informed consent before enrollment;~* Adult male or female, ages 18 to 40 years (inclusive) at the time of enrollment;~* Non-pregnant, non-lactating female;~* Free of clinically significant health problems, as determined by pertinent medical history and clinical examination at study screening;~* With documented history of pertussis immunization (at least 4 doses);~* Women of childbearing potential with a negative pregnancy test at entry;~* Females of childbearing potential who are willing to use an effective method of contraception.~Exclusion Criteria:~* Prior dTpa immunization within the last 10 years or prior dT immunization within the last 2 years, or any other investigational vaccine likely to impact on interpretation of the trial data;~* Suspected or confirmed pertussis infection within the last 10 years or documented pertussis infection in a household member within the last 10 years;~* Receipt of licensed vaccines within 14 days of planned study immunization (30 days for live vaccines) or ongoing participation in another clinical interventional trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Viaskin PT 25 mcg (Type: EXPERIMENTAL): Viaskin PT 25 mcg
- Viaskin PT 50 mcg (Type: EXPERIMENTAL): Viaskin PT 50 mcg
- Viaskin PT Placebo (Type: PLACEBO_COMPARATOR): Viaskin PT Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete